Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Both familial Parkinson's disease mutations accelerate alpha-synuclein aggregation.

L Narhi1, S J Wood, S Steavenson

  • 1Amgen, Inc., Thousand Oaks, California 91320-1789, USA.

The Journal of Biological Chemistry
|March 27, 1999
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intracavity adaptive optics. 3: Hsuria performance.

Applied optics·2010
Same author

Intracavity adaptive optics. 2: Tilt correction performance.

Applied optics·2010
Same author

Intracavity adaptive optics. 1: Astigmatism correction performance.

Applied optics·2010
Same author

Parkinson's disease-associated alpha-synuclein is more fibrillogenic than beta- and gamma-synuclein and cannot cross-seed its homologs.

The Journal of biological chemistry·2000
Same author

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE.

Science (New York, N.Y.)·1999
Same author

Analysis of fibril elongation using surface plasmon resonance biosensors.

Methods in enzymology·1999

Parkinson's disease (PD) involves alpha-synuclein protein aggregation. Specific PD mutations accelerate this aggregation, suggesting it's a key step in disease development.

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Parkinson's disease (PD) is a neurodegenerative disorder characterized by Lewy bodies, primarily composed of alpha-synuclein filaments.
  • The pathogenic mechanism of alpha-synuclein mutations, the only known genetic causes of PD, remains unclear.

Purpose of the Study:

  • To investigate the aggregation properties of wild-type and mutant alpha-synuclein in vitro.
  • To determine the role of PD-linked mutations in alpha-synuclein aggregation.

Main Methods:

  • Incubation of wild-type and mutant alpha-synuclein at physiological temperature.
  • Monitoring the formation of insoluble fibrillar aggregates using in vitro methods.

Main Results:

Related Experiment Videos

  • Both wild-type and mutant alpha-synuclein formed insoluble aggregates with antiparallel beta-sheet structure.
  • PD-linked mutations (A30P and A53T) significantly accelerated aggregate formation compared to wild-type alpha-synuclein.
  • Lag times for aggregate formation were 280h (wild-type), 180h (A30P), and 100h (A53T).

    • Conclusions:

    • Alpha-synuclein aggregation is a critical step in Parkinson's disease pathogenesis.
    • PD-associated mutations accelerate alpha-synuclein aggregation, providing insight into disease mechanisms.